1e
19
1
49
2
2
18
1b
1d
18
34
69
1d
2 29
1d
25
Amy S. Clark, MD, MSCE
78
69
Jill and Alan Miller Associate Professor in Breast Cancer Excellence
28
6d
3
5f
Attending, Hospital of the University of Pennsylvania
a0
Physician Lead, Breast Cancer Clinical Research Unit, University of Pennsylvania, Abramson Cancer Center
95
Medical Director, Clinical Research Unit , University of Pennsylvania, Abramson Cancer Center
11
Department: Medicine
4
1
b
1d
46
Contact information
4e
4
3
3
3
2
4
b
1f
4e
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-154
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-154
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 215-662-7096
32 Fax: 215-615-3349
24
91
32 Fax: 215-615-3349
24
Email:
amy.clark@uphs.upenn.edu
12
amy.clark@uphs.upenn.edu
13
Education:
21 7 BS 14 (Biology) c
2a Haverford College, 1999.
21 7 MD 15 (Medicine) c
49 Milton S. Hershey Penn State College of Medicine, 2006.
21 9 MSCE 22 (Clinical Epidemiology) c
33 University of Pennsylvania, 2012.
c
3
3
3
3
8d
Permanent link21 7 BS 14 (Biology) c
2a Haverford College, 1999.
21 7 MD 15 (Medicine) c
49 Milton S. Hershey Penn State College of Medicine, 2006.
21 9 MSCE 22 (Clinical Epidemiology) c
33 University of Pennsylvania, 2012.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
cb I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.71
Description of Research Expertise
102 My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.e 29
23
156 Stringer-Reasor E, Li Y, Zhang J, Rocque G, Jones K, O'Sullivan C, Giridhar K, Dees EC, Nanda R, Hunter N, Clark A, Wolff A, Krop I, Lin N, Rimawi MF, Yang ES.: CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy 3b J Natl Compr Canc Netw. Mar 2026.
114 Phun J, Clark A, Zhang J, Nayak, A: Discordant HER2 Results Highlight the Need for Compulsory Biomarker Slide Review in Breast Cancer Referrals. The United States and Canadian Academy of Pathology’s 115th Annual Meeting 1e Mar 2026.
16a Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA; ADAPT Consortium. : The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy 2f Cancer Cell. Mar 2026.
173 Jung W, Ko K, Smith AM, Huang A, Xia C, Martei YM, Narayan VK, Clark AS, Lefebvre B, McDermott K, Koropeckyj-Cox D, Fasan O, Hutsell A, Daniels A, Englefield V, Leger KJ, Getz KD, Narayan HK, Marshall JD, Powell-Wiley TM, Yancy CW, Ky B. : Air Pollution and Cardiac Remodeling and Function in Patients With Breast Cancer 33 JAMA Netw Open. Jan 2026.
f8 Clark, A.S., : Missingness in Eligibility Criteria for Target Trial Emulation in EHR with Survival Outcomes. Statistics in Medicine Accepted 2026 Notes: Article ID: SIM70500.
1b0 Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. : Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors 2e Nat Commun. Dec 2025.
21d Chien, J., Mukhtar, R.A., Yau, C., Elias, A. D., Wallace, A. M., Chan, N., Omene, C., Tseng, J., Trivedi, M. S., Stringer-Reasor, E., Yee, D., Clark, A. S., Thomas, A., Han, H., Arora, M., Nangia, C., Albain, K., Falkson, C., Isaacs, C., Zimmer, A., Rozenblit, M., van 't Veer, L., Swigart, L. B., Hirst, G. L., Symmans, W. F., Borowsky, A. D., Onishi, N., Hylton, N., Alkhafaji, S., Giridhar, K. V., Vaklavas, C., Wei, M., Goetz, M. P., Chen, N., Olopade, O., Huppert, L., Wu, C., Esserman, L. J. df : I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients (pts) with HR+ HER2- Stage 2/3 breast cancer (BC) 2 72 San Antonio Breast Cancer Symposium, San Antonio, TX Dec 2025 Notes: Poster Presentation
215 J. Tchou, A. Nayak, H. N. Xu, J. Kollmar, E. H. Smith, M. Z. Mazur, L. Keele, A. Clark, N. Taunk, J. Fraietta, the BreastVax Study Team: Abstract PS4-07-15: A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study San Antonio Breast Cancer Symposium, San Antonio, TX Dec 2025.
1a0 Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropeckyj-Cox D, Zhang L, Liu PP, Landsburg D, Clark AS, Shah PD, Hubbard RA, Huang A, Golec S, Hewitt M, Wilcox NS, Chen Z, Rethy L, Jung W, Ko K, Narayan V, Martei YM, Lang NN, Januzzi JL, Felker GM, Ky B.: Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical Trial 32 JAMA Netw Open. Dec 2025.
2c
7
1d
1f
Selected Publications
17e Ana C. Garrido-Castro1, Tianyu Li2, Se Eun Kim2, Jennifer Desrosiers1, Rita Nanda3, Yara Abdou4, Amy S. Clark5, Ruth Sacks6, Thomas O’Connor1, Natalie Sinclair1, Steve Lo7, Grace Audahl1, Eileen Wrabel1, Tess O’Meara1, Tanya E. Keenan1,8*, Nancy U. Lin1, Harold J. Burstein1, Elizabeth A. Mittendorf1, Nabihah Tayob2, Sara M. Tolaney1 c1 : SACI-IO HR+: Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative metastatic breast cancer 4b 2026 ESMO Breast Cancer Annual Congress May 2026.156 Stringer-Reasor E, Li Y, Zhang J, Rocque G, Jones K, O'Sullivan C, Giridhar K, Dees EC, Nanda R, Hunter N, Clark A, Wolff A, Krop I, Lin N, Rimawi MF, Yang ES.: CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy 3b J Natl Compr Canc Netw. Mar 2026.
114 Phun J, Clark A, Zhang J, Nayak, A: Discordant HER2 Results Highlight the Need for Compulsory Biomarker Slide Review in Breast Cancer Referrals. The United States and Canadian Academy of Pathology’s 115th Annual Meeting 1e Mar 2026.
16a Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA; ADAPT Consortium. : The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy 2f Cancer Cell. Mar 2026.
173 Jung W, Ko K, Smith AM, Huang A, Xia C, Martei YM, Narayan VK, Clark AS, Lefebvre B, McDermott K, Koropeckyj-Cox D, Fasan O, Hutsell A, Daniels A, Englefield V, Leger KJ, Getz KD, Narayan HK, Marshall JD, Powell-Wiley TM, Yancy CW, Ky B. : Air Pollution and Cardiac Remodeling and Function in Patients With Breast Cancer 33 JAMA Netw Open. Jan 2026.
f8 Clark, A.S., : Missingness in Eligibility Criteria for Target Trial Emulation in EHR with Survival Outcomes. Statistics in Medicine Accepted 2026 Notes: Article ID: SIM70500.
1b0 Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. : Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors 2e Nat Commun. Dec 2025.
21d Chien, J., Mukhtar, R.A., Yau, C., Elias, A. D., Wallace, A. M., Chan, N., Omene, C., Tseng, J., Trivedi, M. S., Stringer-Reasor, E., Yee, D., Clark, A. S., Thomas, A., Han, H., Arora, M., Nangia, C., Albain, K., Falkson, C., Isaacs, C., Zimmer, A., Rozenblit, M., van 't Veer, L., Swigart, L. B., Hirst, G. L., Symmans, W. F., Borowsky, A. D., Onishi, N., Hylton, N., Alkhafaji, S., Giridhar, K. V., Vaklavas, C., Wei, M., Goetz, M. P., Chen, N., Olopade, O., Huppert, L., Wu, C., Esserman, L. J. df : I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients (pts) with HR+ HER2- Stage 2/3 breast cancer (BC) 2 72 San Antonio Breast Cancer Symposium, San Antonio, TX Dec 2025 Notes: Poster Presentation
215 J. Tchou, A. Nayak, H. N. Xu, J. Kollmar, E. H. Smith, M. Z. Mazur, L. Keele, A. Clark, N. Taunk, J. Fraietta, the BreastVax Study Team: Abstract PS4-07-15: A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study San Antonio Breast Cancer Symposium, San Antonio, TX Dec 2025.
1a0 Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropeckyj-Cox D, Zhang L, Liu PP, Landsburg D, Clark AS, Shah PD, Hubbard RA, Huang A, Golec S, Hewitt M, Wilcox NS, Chen Z, Rethy L, Jung W, Ko K, Narayan V, Martei YM, Lang NN, Januzzi JL, Felker GM, Ky B.: Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical Trial 32 JAMA Netw Open. Dec 2025.
2c